John P Sharp
Chief Financial Officer at Skye Bioscience, Inc. (SKYE) since March 2026
John P Sharp has filed 8 insider reports with the SEC since February 2021, as chief Financial Officer at Skye Bioscience, Inc. (SKYE) and officer at PhaseBio Pharmaceuticals Inc (PHAS). The latest filing, on April 29, 2026, is a Form 3: John P Sharp became an insider at Skye Bioscience, Inc. (SKYE).
- Filings
- 8
- Companies
- 2
- Bought on market
- None
- Sold on market
- None
Companies where John P Sharp is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Chief Financial Officersince March 2026 | $1.09 | Apr 29, 2026 | |||||
| Officer | 65,767 | May 24, 2022 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Mar 31, 2026SKYEJohn P Sharp became an insiderForm 3New insider
- May 20, 2022PHASSEC Form 4: Sharp John P was granted 6,026 shares, increasing direct ownership by 10% to 65,767 unitsForm 4Grant or award
- Feb 24, 2022PHASSEC Form 4 filed by Sharp John PForm 4Grant or award
- Nov 19, 2021PHASSEC Form 4: Sharp John P was granted 2,017 shares, increasing direct ownership by 3% to 59,741 unitsForm 4Grant or award
- Nov 3, 2021PHASSEC Form 4: Sharp John P exercised 7,500 shares at a strike of $1.68, increasing direct ownership by 15% to 57,724 unitsForm 4Exercise or conversion of a derivative
- Aug 3, 2021PHASSEC Form 4: Sharp John P exercised 7,500 units of Common Stock at a strike of $1.68, increasing direct ownership by 18% to 50,224 units (Amendment)Form 4Exercise or conversion of a derivative
- Aug 3, 2021PHASSEC Form 4: Sharp John P was granted 7,500 units of Common Stock, increasing direct ownership by 18% to 50,224 unitsForm 4Grant or award
- Feb 5, 2021PHASSEC Form 4 filed by P John SharpForm 4Grant or award
Compare John P Sharp with
- John P Sharp vs Andrew J. Schwab1 shared
- John P Sharp vs Punit Dhillon1 shared
- John P Sharp vs Karen L. Smith1 shared
- John P Sharp vs Christopher Twitty1 shared
- John P Sharp vs Annalisa Jenkins1 shared
- John P Sharp vs Tuan Tu Diep1 shared
Other insiders at the same companies
- Andrew J. SchwabSKYE
- 5AM Partners VII, LLCSKYE
- Punit DhillonSKYE
- Karen L. SmithSKYE
- Christopher TwittySKYE
- Annalisa JenkinsSKYE
- Tuan Tu DiepSKYE
- Deborah H. CharychSKYE
- Paul A. GraysonSKYE
- Kaitlyn ArsenaultSKYE
- Puneet S. AroraSKYE
Questions about John P Sharp
- What is John P Sharp's role at Skye Bioscience, Inc.?
- John P Sharp reports to the SEC as chief Financial Officer at Skye Bioscience, Inc. (SKYE), according to the latest filing on April 29, 2026. John P Sharp has also filed as officer at PhaseBio Pharmaceuticals Inc (PHAS).
- How many shares does John P Sharp own?
- After the latest filing that states it, John P Sharp directly owned 65,767 shares of PhaseBio Pharmaceuticals Inc (PHAS). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has John P Sharp bought or sold stock recently?
- No open-market purchases or sales by John P Sharp are on file. The filings report grant or award and exercise or conversion of a derivative.
- How do I get alerts when John P Sharp files?
- Follow John P Sharp on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by John P Sharp (SEC CIK 0001342894). Totals count each trade once, skipping amendments whose original is on file, from Feb 9, 2021 on. View on SEC EDGAR